Diffusion Pharmaceuticals Inc. , a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today announced that the data from the Phase 1/2 clinical trial evaluating the safety and efficacy of trans sodium crocetinate in newly diagnosed glioblastoma multiforme has been published in the print edition of the peer-reviewed Journal of Neurosurgery . Results from the Phase 1/2 clinical trial in 59 patients showed that 36.3% of the full TSC dose patients were alive at two years, compared to historical two-year survival rates ranging from 27% to 30%.